Clearbridge Health (SGX:1H3) narrowed its attributable loss in the first half of 2025 to SG$1.4 million from SG$2.2 million a year earlier, according to a Thursday filing with the Singapore Exchange.
Loss per share stood at SG$0.0008 compared with SG$0.0038 in the comparable period.
Revenue was up 8% year over year to SG$4.9 million from SG$4.5 million, mainly due to increased revenue from renal care services provided in the Philippines.